[go: up one dir, main page]

AR035234A1 - Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento - Google Patents

Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento

Info

Publication number
AR035234A1
AR035234A1 ARP020101318A ARP020101318A AR035234A1 AR 035234 A1 AR035234 A1 AR 035234A1 AR P020101318 A ARP020101318 A AR P020101318A AR P020101318 A ARP020101318 A AR P020101318A AR 035234 A1 AR035234 A1 AR 035234A1
Authority
AR
Argentina
Prior art keywords
alkyl
compounds
pharmaceutical compositions
substituted
group
Prior art date
Application number
ARP020101318A
Other languages
English (en)
Original Assignee
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery filed Critical Pharmacopeia Drug Discovery
Publication of AR035234A1 publication Critical patent/AR035234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aril- y biaril-piperidinas, que comprenden un compuestos, incluyendo enantiómeros, estereoisómeros, rotámeros, tautómeros, racematos y prodrogas de dicho compuesto, y sus sales farmacéuticamente aceptables o solvatos de dicho compuesto o de dicha prodroga, dicho compuesto tiene la estructura general que se muestra en la fórmula (1), en la cual: Ar1 está seleccionado de las porciones de fórmula (2) a (7); Z es una porción seleccionada del grupo que consiste en R4-CO-, R4SO2-, R4N(R2')CO-, R4'-, y R4'-O-C(O)-; R2 es H, alquilo o alquilo (sustituido con cicloalquilo); R2' es H o alquilo; R3 es una porción seleccionada de los grupos que consisten en H, alquilo, cicloalquilo, alquilo (sustituido con cicloalquilo, alcoxi, o CF3), arilalquilo, alquilarilo, tetrahidrofuranilo, tetrahidropiranilo, R8SO2-, y un radical de fórmula (8); n es un número de 1 a 5; R4 es fenilo (sustituido con R7) o fenilalquilo (sustituido en el fenilo con R7); R4' es una porción seleccionada del grupo que consiste en H, alquilo, cicloalquilo, alquilo (sustituido con cicloalquilo, alcoxi, o CF3), arilalquilo, alquilarilo, tetrahidrofuranilo y tetrahidropiranilo; R5 los números 1-4 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en R7, fenilo, piridilo, tiofenilo, pirimidinilo, piridazinilo y pirazinilo, pudiendo estar estos sustituidos con R7, así también como los N-óxidos de los precedentemente citados piridilo, pirimidinilo, piridazinilo y pirazinilo; R6 los números 1-4 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en H, halógeno, alquilo, OH, alcoxi, NH2, NH-alquilo, N(alquilo)2, CN, CF3, NO2 y CF3O; R7 los números 1-3 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en H, halógeno, alquilo, OH, alcoxi, NH2, NH-alquilo, N(alquilo)2, CN, CF3, NO2, CF3O, -NH-C(O)-alquilo, -CH(O), -metilendioxi, -CH2OH, benzofuran-2-ilo, -O(alquilo), -C(O)alquilo, e indolilo; y R8 está seleccionado del grupo consistente en alquilo, arilalquilo, alquilarilo, arilo, -NH(alquilo), y N(alquilo)2; como antagonistas del receptor MCH, métodos para preparar dichos compuestos, composiciones farmacéuticasque contienen uno o más de los compuestos, métodos para preparar las composiciones farmacéuticas que comprenden uno o más de dichos compuestos, y el uso de dichos compuestos que es para la manufactura de un medicamento para el tratamiento, prevención o mejoramiento de una o más enfermedades asociadas con el receptor MCH. Un compuesto ilustrativo de la presente es el que se muestra en la fórmula (9).
ARP020101318A 2001-04-12 2002-04-10 Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento AR035234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28352301P 2001-04-12 2001-04-12

Publications (1)

Publication Number Publication Date
AR035234A1 true AR035234A1 (es) 2004-05-05

Family

ID=23086443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101318A AR035234A1 (es) 2001-04-12 2002-04-10 Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento

Country Status (11)

Country Link
US (1) US6887889B2 (es)
EP (1) EP1377293B1 (es)
JP (2) JP4280073B2 (es)
AR (1) AR035234A1 (es)
AT (1) ATE460163T1 (es)
CA (1) CA2443672C (es)
DE (1) DE60235617D1 (es)
ES (1) ES2340147T3 (es)
MX (1) MXPA03009353A (es)
PE (1) PE20021081A1 (es)
WO (1) WO2002083134A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
CA2446351A1 (en) 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
EP1443922A1 (en) * 2001-10-25 2004-08-11 Schering Corporation Mch antagonists for the treatment of obesity
IL161717A0 (en) * 2001-11-26 2004-09-27 Schering Corp Piperidine-based mch antagonists for treatment of obesity and cns disorders
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1465635A4 (en) 2002-01-10 2005-04-13 Neurogen Corp MELANIN-CONCENTRATING HORMONIC RECEPTOR LIGANDS: SUBSTITUTED 2- (4-BENZYL-PIPERAZIN-1-YLMETHYL) AND 2- (4-BENZYL-DIAZEPAN-1-YLMETHYL) -1H-BENZOIMIDAZOLE ANALOGUES
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
JPWO2003091216A1 (ja) * 2002-04-25 2005-09-02 住友製薬株式会社 新規ピペリジン誘導体
JP2005538047A (ja) * 2002-05-03 2005-12-15 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ボンベシンアンタゴニスト
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ATE453621T1 (de) * 2002-07-03 2010-01-15 Glaxo Group Ltd Substituierte 4-phenylpiperidinamide als tachykininantagonisten und serotoninwiederaufnahmehemmer
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
CN1330651C (zh) * 2002-11-06 2007-08-08 安姆根有限公司 稠合杂环化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004069798A1 (ja) * 2003-02-10 2004-08-19 Banyu Pharmaceutical Co.,Ltd. ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
CN1777596A (zh) * 2003-02-28 2006-05-24 先灵公司 作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
GB0310724D0 (en) * 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
PL1648878T3 (pl) * 2003-07-24 2009-10-30 Euro Celtique Sa Związki piperydynowe i zawierające je kompozycje farmaceutyczne
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
AU2005228133B2 (en) * 2004-03-24 2011-09-08 Merck Sharp & Dohme Corp. Heteroaryl piperidine glycine transporter inhibitors
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JPWO2005097738A1 (ja) * 2004-04-06 2008-02-28 大日本住友製薬株式会社 新規スルホンアミド誘導体
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
AU2005317846B2 (en) * 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
JP5175736B2 (ja) * 2005-10-28 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジングリシン輸送体阻害剤
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN101395147B (zh) * 2005-12-28 2013-05-29 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008148840A1 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
GB230714A (en) 1924-08-20 1925-03-19 Frederick Charles Bina Improvements in propeller pencils
US2538107A (en) * 1946-07-30 1951-01-16 Sterling Drug Inc 4 aryl-4-aminomethylpiperidine derivatives and their preparation
GB640168A (en) * 1946-07-30 1950-07-12 Sterling Drug Inc Improvements in or relating to the preparation of 4-aryl-4-aminomethyl-piperidine derivatives
US2634275A (en) * 1951-11-07 1953-04-07 Winthrop Stearns Inc 4-acylamino-1-alkyl-4-phenylpi-peridines and method of making same
NL262366A (es) * 1960-03-14
FR1381445A (fr) * 1963-10-23 1964-12-14 Hoechst Ag Composés de pipéridine et leur préparation
FR1477152A (fr) * 1965-04-23 1967-04-14 Yoshitomi Pharmaceutical Procédé de préparation de dérivés de l'indole
US3455940A (en) * 1965-12-07 1969-07-15 Herbert C Stecker Certain halo and dihalo n-substituted salicylamides
US4069223A (en) * 1977-05-02 1978-01-17 G. D. Searle & Co. 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676054B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717802B1 (fr) 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
SE9404438D0 (sv) * 1994-12-21 1994-12-21 Astra Ab New process
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
AU5135998A (en) 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists

Also Published As

Publication number Publication date
ATE460163T1 (de) 2010-03-15
JP2004526761A (ja) 2004-09-02
CA2443672A1 (en) 2002-10-24
CA2443672C (en) 2011-03-29
JP4280073B2 (ja) 2009-06-17
WO2002083134A1 (en) 2002-10-24
MXPA03009353A (es) 2004-02-12
US20030013720A1 (en) 2003-01-16
PE20021081A1 (es) 2002-12-18
JP2009102430A (ja) 2009-05-14
EP1377293A1 (en) 2004-01-07
EP1377293B1 (en) 2010-03-10
DE60235617D1 (de) 2010-04-22
ES2340147T3 (es) 2010-05-31
US6887889B2 (en) 2005-05-03

Similar Documents

Publication Publication Date Title
AR035234A1 (es) Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
AR034116A2 (es) Derivados de piperazinas y piperidinas con efecto analgesico, composiciones farmaceuticas que los contienen, uso de los mismos para la fabricacion de un medicamento y un proceso para la preparacion de dichos compuestos
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
PA8609201A1 (es) Piridinonas sustituidas
AR054799A1 (es) Derivados de oxindol
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
UY27503A1 (es) Nuevos derivados de piperazina
RU2007101685A (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR019190A1 (es) Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure